publication date: Jan. 17, 2020

NCI Trials

NCI Trials for Jan. 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – PEPN1812

A Phase I Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Pediatric Early Phase Clinical Trial Network

Lamble, Adam Joseph

(206) 987-9546


Phase I/II – 10276

A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Rutgers University – Cancer Institute of New Jersey LAO

Spencer, Kristen Renee

(732) 235-3378


Phase I/II – 10296

Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation

University of Texas MD Anderson Cancer Center LAO

Murthy, Rashmi Krishna

(713) 792-2817


Phase I/II – 10301

A Phase I and  Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Duke University – Duke Cancer Institute LAO

Gay, Hiram Alberto

(314) 362-8516


Phase II—10302

Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

Rutgers University – Cancer Institute of New Jersey LAO

Malhotra, Jyoti

Continue reading NCI Trials for Jan. 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.